Costs of Inflammatory Bowel Disease in Germany

Renee Stark (), Hans-Helmut König and Reiner Leidl

PharmacoEconomics, 2006, vol. 24, issue 8, 797-814

Abstract: Introduction: Inflammatory bowel disease (IBD) is a chronic condition that afflicts young adults in their economically productive years. The goal of this study was to determine the costs of IBD in Germany from a societal perspective, using cost diaries. Methods: Members of the German Crohn’s Disease and Ulcerative Colitis Association who had IBD were recruited by post, and those who agreed to participate documented their IBD-associated costs prospectively in a diary over 4 weeks. They documented their use of healthcare facilities, medications, sick leave and out-of-pocket expenditures, as well as general demographic information, the status and history of their IBD, and long-term disability. Item costs were calculated according to national sources. Cost data were calculated using non-parametric bootstrapping and presented as mean costs (year 2004) over 4 weeks. Results: The cost diaries were returned by 483 subjects (Crohn’s disease: n=241, ulcerative colitis: n=242) with a mean age of 42 years and an average disease duration of 13 years (SD ± 8.09). The cost diaries were regarded as ‘easy to complete’ by 89% of participants. The mean 4-week costs per subject were €1425 (95% CI 1201, 1689) for Crohn’s disease and €1015 (95% CI 832, 1258) for ulcerative colitis. Of the total costs for Crohn’s disease, 64% were due to indirect costs such as early retirement or sick leave and 32% were due to direct medical costs. In contrast, of the total costs for ulcerative colitis, 41% were due to direct medical costs and 54% to indirect costs. Conclusions: This is the first comprehensive cost study for Crohn’s disease and ulcerative colitis in Germany. The most important economic factors that influenced the cost profiles of both diseases were the long-term productivity losses due to an ongoing inability to work and the cost of medications. Results indicate significant cost differences between Crohn’s disease and ulcerative colitis. This data provides initial cost estimates that can be analysed further with respect to cost determinants and disease-specific costs in the future. Copyright Adis Data Information BV 2006

Date: 2006
References: View complete reference list from CitEc
Citations: View citations in EconPapers (7)

Downloads: (external link)
http://hdl.handle.net/10.2165/00019053-200624080-00006 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:24:y:2006:i:8:p:797-814

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.2165/00019053-200624080-00006

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().